Alembic Pharmaceuticals Limited (NSE: APLLTD)
India
· Delayed Price · Currency is INR | Market Cap | 203.53B |
| Revenue (ttm) | 63.57B |
| Net Income (ttm) | 6.47B |
| Shares Out | 196.56M |
| EPS (ttm) | 32.89 |
| PE Ratio | 31.48 |
| Forward PE | 27.37 |
| Dividend | 11.00 (1.05%) |
| Ex-Dividend Date | Jul 15, 2024 |
| Volume | 25,553 |
| Open | 1,045.50 |
| Previous Close | 1,045.20 |
| Day's Range | 1,032.10 - 1,054.50 |
| 52-Week Range | 746.50 - 1,303.90 |
| Beta | 0.69 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 4, 2025 |
About Alembic Pharmaceuticals
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ... [Read more]
Financial Performance
In 2023, Alembic Pharmaceuticals's revenue was 62.29 billion, an increase of 10.19% compared to the previous year's 56.53 billion. Earnings were 6.16 billion, an increase of 80.07%.
Financial StatementsNews
Alembic Pharmaceuticals shares surge nearly 3% on USFDA approval for Divalproex Sodium Capsules
Shares of Alembic Pharmaceuticals saw a sharp uptick of 2.38% on December 20, 2024, trading at ₹1,072.75, following the company’s announcement of receiving final approval from the USFDA for its Abbrev...
Alembic Pharmaceuticals secures USFDA approval for Divalproex Sodium Delayed-Release Capsules USP, 125 mg
Alembic Pharmaceuticals Limited, a prominent player in the global pharmaceutical industry, announced on December 20, 2024, that it has received final approval from the United States Food & Drug Admini...
Alembic Pharmaceuticals completes ANVISA GMP Audit for API-II Facility in Brazil
Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed the GMP audit conducted by the Brazilian Health Regulatory Agency (ANVISA) for its API-II facility i...
Alembic Pharmaceuticals receives tentative USFDA approval for olopatadine hydrochloride solution
Alembic Pharmaceuticals Limited has secured tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for olopatadine hydrochloride ophthalmic s...
Alembic Pharma shares surged nearly 5% today
Alembic Pharmaceuticals shares surged nearly 5% today – as of 9:35 am the shares were trading 4.33% higher at ₹1,086.95 on NSE. Alembic Pharmaceuticals faced a setback as the United States Food and Dr...
Alembic Pharmaceuticals secures USFDA approval for Ivabradine tablets
Alembic Pharmaceuticals Limited (Alembic) recently informed exchanges that the US Food and Drug Administration (USFDA) has granted Final Approval for its Abbreviated New Drug Application (ANDA) Ivabra...
Alembic Pharmaceuticals gains USFDA final approval for Diltiazem Hydrochloride extended-release capsules
Alembic Pharmaceuticals Limited has announced that it has received final approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Diltiazem Hydro...
Alembic Pharma Q2 FY25 Results: Revenue jumps 3.3% YoY to ₹1,647.98 crore, net profit jumps 12.2% YoY
Alembic Pharmaceuticals reported its financial results for Q2 FY25, showing positive year-over-year (YoY) growth in both revenue and net profit, though quarter-over-quarter (QoQ) figures reflected mod...
Alembic Pharmaceuticals shares surge today – Know More
Alembic Pharmaceuticals saw a rise in its share price today after announcing that it had received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applicati...
Alembic Pharmaceuticals receives USFDA approval for Diltiazem Hydrochloride Extended-Release capsules
Alembic Pharmaceuticals Limited has recently informed exchanges that it has obtained final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for...
Top losers today: DMart down 8.26%, Saregama drops 5.56%, and Tata Chemicals falls 5.04%
At 12:43 PM IST, the market witnessed some significant declines among leading stocks. Below is a table summarizing the top losers: Stock Name Price (₹) Change (%) DMart (Avenue Supermarts) 4,194.95 -8...
Alembic Pharmaceuticals hits 52-week high as its oncology formulations unit successfully completes USFDA inspection
Alembic Pharmaceuticals shares hit a new 52-week high in morning trade after the company successfully completed a USFDA inspection of its Oncology Formulation Facility (F-2) in Panelav with no Form 48...
Alembic Pharmaceuticals successfully completes USFDA inspection at its Oncology Formulation Facility
Alembic Pharmaceuticals has recently informed exchanges that the company has successfully completed a USFDA inspection of its Oncology Formulation Facility (F-2) in Panelav with no Form 483 observatio...
Alembic announces early participation in PM’s internship scheme
Alembic Pharmaceuticals Limited announces its participation in the Prime Minister's internship scheme aimed at providing internship opportunities for one crore young Indians across top companies. Expl...
Alembic Pharmaceuticals receives USFDA approval for Alcaftadine Ophthalmic Solution
Alembic Pharmaceuticals Limited has announced that it received final approval from the U.S. Food and Drug Administration (USFDA) for its over-the-counter (OTC) Alcaftadine Ophthalmic Solution, 0.25%. ...
Alembic Pharmaceuticals shares surge 3% after receiving USFDA final approval for Lamotrigine Extended-Release Tablets
Alembic Pharmaceuticals shares jumped more than 3% in morning trade after the US Food and Drug Administration (USFDA) granted final approval for its Abbreviated New Drug Application (ANDA) for Lamotri...
Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets
Alembic Pharmaceuticals Limited announced today that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Lamotrigine Exten...
Alembic Pharmaceuticals receives USFDA final approval for Paliperidone Extended-Release Tablets
Alembic Pharmaceuticals Limited has announced its receipt of final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Paliperidone Extended-Rel...
Alembic Pharmaceuticals stock surges 4% after getting USFDA approval for Albendazole tablets
Alembic Pharmaceuticals shares jumped more than 4% in early trade after the company received USFDA approval for Albendazole tablets. The US Food and Drug Administration (USFDA) granted Alembic Pharmac...
Alembic Pharmaceuticals share jumps 3% after getting USFDA approval for Albendazole tablets
Alembic Pharmaceuticals saw its share surge today after getting approval from the US Food & Drug Administration (USFDA) for its Albendazole Tablets USP, 200 mg. As of 1:40 PM, the company’s shares wer...
Alembic Pharmaceuticals gets USFDA nod for Albendazole tablets
Alembic Pharmaceuticals Ltd has secured final approval from the US Food & Drug Administration (USFDA) for its Albendazole Tablets USP, 200 mg. This approval is for the company’s Abbreviated New Drug A...
USFDA greenlights Alembic Pharmaceutical’s Betamethasone Valerate Foam
Alembic Pharmaceuticals Limited recently disclosed that the US Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Fo...